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Abstract. Hirsutine is one of the major alkaloids isolated 
from plants of the Uncaria genus and is known for its cardio-
protective, anti-hypertensive and anti-arrhythmic activities. 
We recently reported that hirsutine is an anti-metastatic 
phytochemical by targeting NF-κB activation in a murine 
breast cancer model. In the present study, we further exam-
ined the clinical utility of hirsutine against human breast 
cancer. Among six distinct human breast cancer cell lines, 
hirsutine showed strong cytotoxicity against HER2-positive/
p53-mutated MDA-MB-453 and BT474 cell lines. Conversely, 
HER2-negative/p53 wild-type MCF-7 and ZR-75-1 cell lines 
showed resistance against hirsutine-induced cytotoxicity. 
Hirsutine induced apoptotic cell death in the MDA-MB-453 
cells, but not in the MCF-7 cells, through activation of caspases. 
Furthermore, hirsutine induced the DNA damage response in 
the MDA-MB-453 cells, but not in the MCF-7 cells, as high-
lighted by the upregulation of γH2AX expression. Along with 
the induction of the DNA damage response, the suppression of 
HER2, NF-κB and Akt pathways and the activation of the p38 
MAPK pathway in the MDA-MB-453 cells were observed. 
Considering that there was no difference between MDA-MB-
453 and MCF-7 cells in regards to irinotecan-induced DNA 
damage response, our present results indicate the selective 
anticancer activity of hirsutine in HER2-positive breast cancer 
by inducing a DNA damage response.
Introduction
Breast cancer is the most commonly diagnosed cancer 
among women and is second only to lung cancer in terms of 
cancer-related mortality (1). Despite advances in breast cancer 
research and therapy, the mortality rate remains high (2); 
therefore, the development of new agents for breast cancer 
therapy is clinically important.
Phytochemicals are a promising source for the develop-
ment of novel cancer therapeutics. Due to their potential 
effectiveness and low toxicity proﬁles (3), phytochemicals 
generally have been successful in clinical drug development to 
treat many diseases (4,5). Hirsutine is one of the major alka-
loids found in plants of the Uncaria genus and is known for 
its cardioprotective (6), anti-hypertensive and anti-arrhythmic 
activities (7). Recently, we identified hirsutine as an anti-
metastatic phytochemical by targeting NF-κB activation in a 
murine breast cancer model. We demonstrated the signiﬁcant 
anti-metastatic activity of hirsutine both in vitro and in vivo (8).
In the present study, we further explored the clinical utility 
of hirsutine against breast cancer by testing the effect of 
hirsutine against six human breast cancer cell lines. Notably, 
hirsutine showed selective anticancer activity against human 
breast cancer cell lines with HER2-expressing and p53-mutated 
phenotypes. We further identiﬁed that the induction of DNA 
damage response can be a primary target of hirsutine, leading 
to apoptotic cell death of breast cancer cells.
Materials and methods
Reagents. Hirsutine and a Cell Counting kit were purchased 
from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). 
Muse Annexin V and Dead Cell Assay kits were purchased 
from EMD Millipore Corporation (Merck Millipore, Billerica, 
MA, USA). The reagent for the Caspase-Glo3/7 Assay was 
obtained from Promega (Madison, WI, USA). Irinotecan was 
purchased from Sigma-Aldrich (St. Louis, MO, USA).
Cells. All cell lines used in the present study were obtained 
from the American Type Culture Collection (ATCC). Human 
breast cancer cells ZR-75-1 and BT474 were maintained in 
RPMI-1640 medium containing 10% bovine serum (Nissui, 
Tokyo, Japan). MCF-7, MDA-MB-231, MDA-MB-468 and 
MDA-MB-453 cells were maintained in Dulbecco's modi-
ﬁed Eagle's medium (DMEM) containing 10% bovine serum 
(Nissui). Cells were incubated at 37˚C in a humidiﬁed atmo-
sphere of 95% air and 5% CO2.
Cell viability assay. For detection of the neoplastic activity of 
cells grown in 96-well plates, the human breast cancer cells 
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in exponential growth were placed at a ﬁnal concentration 
of 2x104 cells/well in a 96-well plate. After a 3-h incubation, the 
cells were treated with hirsutine (6.25, 12.5, 25 and 50 µM) or 
with the vehicle (vehicle control, 0.5% DMSO) for 24 h. After 
treatment, 10 µl of WST-1 reagent was added. The microplate 
was incubated for another 2 h in a humidiﬁed atmosphere 
(37˚C, 5% CO2) to allow the formation of formazan dye and 
to get a higher sensitivity. The absorbance was measured in 
a microplate reader at 450/620 nm. Cell viability was deter-
mined from the absorbance of soluble formazan dye generated 
by the living cells.
Detection of apoptosis. Cells were grown in 24-well plates 
and treated with 50 µM of hirsutine for 15 h before assaying 
using Muse™ Cell Analyzer (Merck Millipore). Floating and 
adherent cells were collected after the treatments. The cells 
were washed twice with PBS and resuspended in PBS. The 
apoptosis proﬁling and apoptotic cell counts were obtained 
with Muse Annexin V and Dead Cell Assay kit. The assay was 
conducted in triplicate and in accordance with the manufac-
turer's instructions.
Measurement of caspase activity. For measurements of 
the activities of caspase-3 and caspase-7, the Caspase-Glo® 
3/7 Assay was carried out according to the manufacturer's 
instructions. This kit is based on the cleavage of the amino 
acid sequence DEVD of a luminogenic substrate by caspase-3 
and caspase-7, which results in a luminescent signal. Human 
breast cancer cells in exponential growth were placed at a ﬁnal 
concentration of 1x104 cells/well in 90 µl in a white-walled 
multi-well plate. After 3 h of incubation, the cells were 
treated with hirsutine (25 and 50 µM) or with the vehicle 
(vehicle control, 0.5% DMSO) for another 3 h. Then 100 µl 
of Caspase-Glo® 3/7 reagent was added, and the plates were 
incubated for another 30 min. Caspase-3 and -7 activities were 
recorded in a Glomax Multi-Detection system.
Western blot analysis. Cells were exposed to 50 µM hirsutine 
for 0, 1, 3 and 6 h. Treated cells were collected, washed with 
PBS, and lysed in lysis buffer [25 mM HEPES (pH 7.7), 0.3 M 
NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.1% Triton X-100, 
20 mM β-glycerophosphate, 0.1 mM sodium orthovanadate, 
0.5 mM phenylemethylsulfonyl fluoride (PMSF), 1 mM dithio-
threitol, 10 mg/ml aprotinin, and 10 mg/ml leupeptin]. The cell 
lysates were separated by 5-10% SDS-PAGE and transferred 
to PVDF membranes using a glycine transfer buffer [192 mM 
glycine, 25 mM Tris-HCl (pH 8.8) and 20% (v/v) methanol]. 
After blocking with Block Ace for 4 h at room temperature, 
the membranes were incubated overnight with the primary 
antibodies, and then for 60 min with the secondary antibodies. 
Primary antibodies were used at a dilution of 1:1,000. The 
secondary antibodies were used at a dilution of 1:2,000 and 
visualized with an enhanced chemiluminescence system 
(Amersham Biosciences, Amersham, UK).
The following antibodies from Cell Signaling Technology 
(Danvers, MA, USA) were used for western blot analysis 
according to the manufacturer's recommendations: 
anti-phospho-Akt (Ser473, #9271L), anti-phospho-p65 
(Ser536, #3033S); anti-caspase-3 (#9662S), anti-phospho-p38 
(p-p38) (Thr-180/Tyr-182, #4511), anti-phospho-histone H2AX 
(Ser139, #9947). Anti-actin (sc-1615, #G1312), anti-caspase-9 
(sc-7885, #B0807), anti-ErbB2 (sc-284, #L0706), anti-p65 
(sc-109G, #J1003), anti-Akt1 (sc-1618, #131705) and 
anti-p38α (sc-535, #K1010) were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA).
Statistical analysis. All the data are expressed as mean ± SD 
of at least 3 independent experiments and were analyzed for 
statistical signiﬁcance using the Student t-test. P-values <0.05 
were considered statistically signiﬁcant.
Results
Selective cytotoxicity of hirsutine against human breast 
cancer cells. We recently found hirsutine as an anti-metastatic 
phytochemical by targeting NF-κB activation in a murine 
breast cancer model. To further extend the utility of hirsutine, 
we examined the anticancer effect of hirsutine against human 
Figure 1. Selective cytotoxic effect of hirsutine on human breast cancer cell 
lines. Human breast cancer cells in exponential growth were placed at a ﬁnal 
concentration of 2x104 cells/well in a 96-well plate and incubated for 3 h. 
After incubation, the cells were treated with hirsutine (6.25, 12.5, 25 and 
50 µM) or with the vehicle (vehicle control, 0.5% DMSO) for 24 h. After 
treatment, 10 µl of WST-1 reagent was added. The microplate was incubated 
for another 2 h to allow the formation of formazan dye and to obtain a 
higher sensitivity. The absorbance was measured in a microplate reader at 
450/620 nm. Cell viability was determined from the absorbance of soluble 
formazan dye generated by the living cells.
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breast cancer cell lines with distinct molecular background. 
Among the 6 tested human breast cancer cell lines, hirsutine 
showed strong cytotoxicity against the MDA-MB-453 and 
BT474 cell lines that have HER2-positive and p53-mutated 
characteristics (Fig. 1, top panel). While triple-negative breast 
cancer cell lines MDA-MB-231 and MDA-MB-468 showed 
a moderate response (Fig. 1, middle panel), HER2-negative 
and p53 wild-type MCF-7 and ZR-75-1 cells showed signiﬁ-
cant resistance against hirsutine-induced cytotoxicity (Fig. 1, 
bottom panel).
Induction of breast cancer cell apoptosis by hirsutine. 
To examine whether the cytotoxic effect of hirsutine is a 
result of the induction of apoptosis, both hirsutine sensitive 
(MDA-MB-453) and resistant (MCF-7) cells were subjected 
to Annexin V staining 15 h after treatment with hirsutine. In 
concert with the hirsutine-induced cytotoxicity (Fig. 1), hirsu-
tine signiﬁcantly induced apoptosis in the MDA-MB-453 cells, 
but not in the MCF-7 cells (Fig. 2). Such induction of apoptosis 
by hirsutine was related to the activation of caspases, as noted 
in the elevated caspase-3/7 activity in the MDA-MB-453 cells, 
but not in the MCF-7 cells, 3 h after treatment with hirsutine 
(Fig. 3). This demonstrated that caspases played an important 
role in hirsutine-induced apoptosis in the MDA-MB-453 cells. 
These results clearly show that the induction of apoptotic cell 
death can be a potential mechanism for the selective anticancer 
effect of hirsutine against human breast cancer cells.
Hirsutine induces a DNA damage response in breast cancer 
cells. To further explore the possible mechanism of hirsutine 
to induce apoptosis in breast cancer cells, we assessed its effect 
on the MAPK, HER2, NF-κB, and Akt signaling pathways, 
as well as the DNA damage response. As shown in Fig. 4, 
hirsutine signiﬁcantly suppressed the HER2, NF-κB, and Akt 
signaling pathways in the MDA-MB-453 cells. Meanwhile, 
the activation of the p38 MAPK stress pathway and a DNA 
damage response, as noted in the expression of p-p38 and 
γH2AX, respectively, were observed upon hirsutine treatment 
in the MDA-MB-453 cells. Conversely, hirsutine did not show 
any signiﬁcant effect on those molecular pathways or DNA 
damage response in the MCF-7 cells. In order to determine the 
selectivity of hirsutine to induce the DNA damage response 
in HER2-positive and p53-mutant breast cancer cells, we used 
irinotecan as a typical DNA damage-inducing agent to assess 
its effects on the MCF-7 and MDA-MB-453 cells. As shown 
Figure 2. Effect of hirsutine on apoptotic cell death in the MDA-MB-453 
and MCF-7 cells. MDA-MB-453 and MCF-7 cells were grown in 24-well 
plates and treated with 50 µM of hirsutine for 15 h before assaying using the 
Muse™ Cell Analyzer. Floating and adherent cells were collected after the 
treatments. Cells were washed twice with PBS and re-suspended in PBS. The 
apoptosis proﬁling and apoptotic cell counts were obtained with the Muse 
Annexin V and Dead Cell Assay kit. The assay was conducted in triplicate 
and in accordance to the manufacturer's instructions. *P<0.05.
Figure 3. Effect of hirsutine on activities of caspases in the MDA-MB-453 
and MCF-7 cells. The human breast cancer cells in exponential growth were 
placed at a ﬁnal concentration of 1x104 cells/well in 90 µl in a white-walled 
multi-well plate. After 3 h of incubation, the cells were treated with hirsutine 
(25 and 50 µM) or with the vehicle (vehicle control, 0.5% DMSO) for another 
3 h. Then 100 µl of Caspase-Glo® 3/7 reagent was added, and the plates were 
incubated for another 30 min. Caspase-3 and -7 activities were recorded in a 
GloMax Multi Detection system. *P<0.05.
Figure 4. Effects of hirsutine on the DNA damage response in the 
MDA-MB-453 and MCF-7 cells. Cells were exposed to 50 µM hirsutine for 
0, 1, 3 and 6 h. Cell lysates were collected and subjected to western blot 
analysis to detect the expression of related proteins. Results are representa-
tive of at least 3 independent experiments showing similar results.
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in Fig. 5, irinotecan signiﬁcantly upregulated γH2AX and 
p-p38 expression in both the MCF-7 and MDA-MB-453 cells, 
in contrast to hirsutine. Collectively, these results suggest the 
selective activity of hirsutine to induce DNA damage response 
in HER2-positive and the p53-mutated human breast cancer 
cells.
Discussion
In the present study, we investigated the clinical utility of 
hirsutine, an indol alkaloid phytochemical compound present 
in plants of the Uncaria genus, as an anticancer agent for 
human breast cancer cells. We found that the HER2-positive/
p53-mutated MDA-MB-453 and BT474 cell lines were rela-
tively sensitive to hirsutine-induced cytotoxicity among the 
6 tested human breast cancer cell lines (Fig. 1). To exert its 
cytotoxic activity against breast cancer cells, hirsutine induced 
apoptosis along with the activation of caspases (Figs. 2 and 3). 
Importantly, the expression of γH2AX, a hallmark of DNA 
damage response, was signiﬁcantly upregulated after treat-
ment of hirsutine along with the p38/MAPK stress signaling 
pathways (Figs. 4 and 5) implying that a DNA damage response 
was involved in the hirsutine-induced apoptosis.
Apoptosis is a programmed cell death occurring in 
multicellular organisms (9). In general, drug-induced 
apoptosis is one major mechanism of action for treating 
cancer, and various signaling pathways are involved in the 
process (10). Among these, a DNA damage response is one of 
the molecular events leading to apoptosis, and indeed many 
anticancer agents induce a DNA damage response (11-15). 
The mechanism involved in DNA damage-induced apoptotic 
cell death is known to closely correlate with the DNA repair 
response (16-18). The phosphorylation of the Ser-139 residue 
of the histone variant H2AX, forming γH2AX, is known as 
an early cellular response associated with the induction of 
DNA double-strand breaks. Therefore, induction of γH2AX 
has been considered as a hallmark of a DNA damage 
response (19-22). We originally identiﬁed hirsutine to inhibit 
NF-κB activation (8), and the NF-κB pathway is known to play 
an important role in cancer progression (23-30). The NF-κB 
pathway can be activated as part of the DNA damage response 
by orchestrating cellular survival pathways (31,32). Indeed, we 
observed the downregulation of p-p65 in the MDA-MB-453 
cells, but not in the MCF-7 cells, in response to hirsutine treat-
ment along with the inhibition of Akt activity (Fig. 4), which 
has been widely recognized as an important determinant for 
DNA damage-induced apoptosis (33,34) and double-strand 
break repair (35-37). Considering the upregulation of p-Akt 
in MCF-7 cells following hirsutine treatment along with 
resistance to its cytotoxicity, the NF-κB/Akt pathway may 
be involved in the selective resistance of MCF-7 cells against 
hirsutine.
In addition to the NF-κB/Akt pathway, p38 MAPK activity 
is also known to play an important role in the DNA damage 
response induced by genotoxic stress with DNA-damaging 
chemotherapeutic agents through the activation of p53 (38). 
Inhibition of the p38 MAPK pathway reduced γH2AX 
expression (39), diminished the apoptotic fraction of cells and 
increased cell survival following exposure to chemotherapeutic 
agents (15,38,40), thus suggesting a role for p38 activation in 
the apoptotic response against genotoxic stress. Consistently, 
we observed the upregulation of p-p38 upon hirsutine treat-
ment in the MDA-MB-453 cells, but not in the MCF-7 cells. 
In the context of selective cytotoxicity, hirsutine treatment 
downregulated the expression of HER2 in the MDA-MB-453 
cells (Fig. 4), which has been known to be involved in the 
repair response of DNA damage induced by chemotherapeutic 
agents (41,42). Importantly, we obtained similar results of the 
DNA damage response in HER2-positive BT474 cells (data 
not shown). Furthermore, by using the anticancer drug irino-
tecan (CPT-11), which is a topoisomerase I inhibitor (43-47), 
we did not observe a selective induction of DNA damage 
response between the MDA-MB-453 and MCF-7 cells (Fig. 5). 
Considering the differential status of HER2 expression and/
or p53 mutation between the MDA-MB-453 and MCF-7 
cells (48-50), HER2 expression and/or p53 status is presum-
ably involved in determining the cellular response to hirsutine 
treatment. Although further study is clearly required to deter-
mine the exact mechanisms of action by which hirsutine targets 
cancer cells, our present study clearly demonstrated the selec-
tive anticancer activity of hirsutine against HER2-positive 
breast cancer cells by inducing DNA damage, implying its 
clinical utility as a novel anticancer drug.
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